Lipitor to be tested in Alzheimer's

11 July 2001

Pfizer's lipid-lowering drug Lipitor (atorvastatin) is to be tested ina clinical trial in patients with mild Alzheimer's disease, coordinated by the US Institute for the Study of Aging. This is thought to be the first time that a statin has been clinically tested in AD. The premise for the study is that increased cholesterol has been linked to an AD-like pathology in the brain, with epidemiological studies suggesting a correlation between cardiovascular disease, dyslipidemia and AD. Final results of the Phase II study are expected in 2003.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight